Sign in Subscribe
Biotechnology industries

Aventis Faces Crucial Deadline in Bid Battle Against Sanofi-Synthelabo

Strategic Insights

— 1 min read

French pharmaceutical giant Aventis SA is waiting anxiously for a judge's ruling on March 1, which will determine how much time it has to find a white knight to help fend off a €48.5 billion hostile bid from Paris-based rival Sanofi-Synthelabo SA. The company's executive chairman, Igor Landau, has estimated the bid battle could last up to five months, giving Aventis more time to search for an alternative partner. Meanwhile, rumors of a possible alliance with Novartis AG are swirling, but neither party has confirmed any talks.

Key Takeaways:

  • Aventis is waiting for a judge's ruling on March 1 to determine the timetable to hear its legal challenges against the French financial markets regulator's approval of Sanofi-Synthelabo's bid.
  • The bid battle is estimated to last up to five months, giving Aventis more time to search for an alternative partner.
  • Rumors of a possible alliance between Aventis and Novartis AG are circulating, but neither company has confirmed any talks.
  • Novartis would face several disadvantages if it were to launch a competing offer for Aventis, including requiring a premium to Sanofi's offer and potential job cuts.
  • The potential acquisition of Aventis would put pressure on Novartis to seek greater cost savings, which could lead to job losses and negatively impact relations with labor unions and governments in Germany and France.
  • Aventis shares rose 1.24% to €61.15 in Paris, while Novartis shares eased 0.35% to Sfr 56.65 ($44.70).

Statistics:

  • €48.5 billion: The value of Sanofi-Synthelabo's hostile bid for Aventis SA
  • $60.3 billion: equivalent value of Sanofi-Synthelabo's hostile bid for Aventis SA in US dollars
  • 35 days: The normal duration of an offer period for a takeover bid
  • 5 months: Estimated duration of the bid battle between Aventis and Sanofi-Synthelabo
  • 1.24%: Increase in Aventis shares on Thursday
  • €61.15: Closing price of Aventis shares in Paris
  • Sfr 56.65: Closing price of Novartis shares in Switzerland
  • €54.75: Closing price of Sanofi shares in Paris

Sources:

  • "Aventis Faces Critical Deadline in Bid Battle" by Ross Tieman
  • Bloomberg: "Aventis Shares Rise as Investors Halt Stakes to Be Possible"

Read more